

1. Record Nr.	UNINA9910488718103321
Titolo	Direct oral anticoagulants : from pharmacology to clinical practice // Riccardo Proietti [and four others], editors
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	3-030-74462-0
Descrizione fisica	1 online resource (283 pages)
Disciplina	615.718
Soggetti	Anticoagulants (Medicine) Anticoagulants (Medicina) Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di contenuto	Intro -- Contents -- 1: The Coagulative Cascade -- Introduction -- The Cell-Based Model of Blood Coagulation -- The Effect of Oral Anticoagulants on the Coagulation Cascade -- Conclusions -- References -- 2: Clinical Indications for Direct Acting Oral Anticoagulants -- Introduction -- Nonvalvular Atrial Fibrillation -- Venous Thromboembolism -- Coronary Artery Disease -- Left Ventricular Thrombus -- Rheumatic Heart Disease -- Heparin-Induced Thrombocytopenia -- Myocardial Injury After Noncardiac Surgery -- Heart Failure in Sinus Rhythm -- Embolic Stroke of Undetermined Source -- Mechanical Valves -- Left Ventricular Assist Device -- References -- 3: Pharmacokinetics and Pharmacodynamics of DOAC -- Introduction -- Physico-Chemical Properties -- Pharmacodynamics of DOACs -- Mechanism of Action -- Pharmacokinetics of DOACs -- Absorption -- Distribution -- Metabolism -- Excretion -- Conclusions -- References -- 4: Drug-Drug Interaction with DOACs -- Introduction -- General Considerations -- DDI with Antiarrhythmic Drugs -- DDI with Antiplatelet and Antithrombotic Drugs -- DDI with NSAIDs Drugs -- DDI with Statins and Lipid-Modifying Agents -- DDI with Antibiotics and Antifungal Drugs -- DDI with Antacid Drugs -- DDI with Antineoplastic and Immune-Modulating Agents -- DDI with Antiepileptic Drugs -- DDIs with Anti-Human Immunodeficiency

(HIV) and Anti-Hepatitis C Virus (HCV) Drugs -- DDIs with Monoclonal Antibodies and Interleukin 6 (IL6) -- Conclusions -- References -- 5: Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery -- Introduction -- Indications for Reversal -- Emergency Surgery and Urgent Procedures -- Life-Threatening and Uncontrolled Bleeding -- General Approach -- Assessment of Anticoagulation Status -- Specific and Nonspecific Agents -- Dabigatran Reversal: Idarucizumab (Praxbind®) -- Clinical Pharmacology.

Dosage and Administration -- Efficacy and Safety -- Use in Clinical Practice -- Factor Xa Inhibitor (Rivaroxaban and Apixaban) Reversal: Andexanet Alfa (Andexxa® -- Ondexxya®) -- Clinical Pharmacology -- Dosage and Administration -- Efficacy and Safety -- Use in Clinical Practice -- Other Pro-Hemostatic Therapies -- Clotting Factor Products -- Other -- The Search of a Universal Antidote -- Ciraparantag --

FXa16L -- Conclusions -- References -- 6: Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation -- Introduction -- Risk Stratification:

An Overview -- Embolic Risk Stratification -- CHADS2 -- CHA2DS2VASc -- R2CHADS2 Score -- Atria Stroke Score -- QStroke Score -- Garfield AF -- ABC Stroke Risk Score -- Bleeding Risk Assessment -- The HAS-BLED Score -- Direct Oral Anticoagulants in AF: General Outline -- DOACs and Risk Stratification -- DOACs Efficacy and Safety in Patients with AF and Diabetes -- DOACs and Heart Failure -- DOACs and Age 75 -- DOACs and Hypertension -- DOACs and Previous Stroke/TIA -- DOAC Efficacy and Safety in Female Patients with AF -- DOACs and Kidney Disease -- DOACs and Cirrhosis -- Anticoagulant Selection -- DOACs Registration Trials -- Oral Anticoagulant Selection -- New Scenarios in the Risk Stratification Panorama -- New Clinical Risk Factors -- BMI -- Echocardiography -- Biomarkers -- New Scores -- References -- 7:

Use of DOAC in Patients with Kidney Disease -- Introduction -- Non-End-Stage Kidney Disease -- End-Stage Kidney Disease -- Patients on Dialysis -- Kidney Transplant Recipients -- Conclusions --

References -- 8: Anticoagulation in Elderly Patients with Atrial Fibrillation Authors -- Introduction -- Indications for Stroke Prevention in Elderly -- Antithrombotic Strategies in Elderly with AF: Anticoagulant Vs. Antiplatelet Therapy.

DOACs in Elderly Patients: Current Evidences -- Dabigatran -- Rivaroxaban -- Apixaban -- Edoxaban -- VKA Versus DOACs in Elderly -- Anticoagulation in Frail Elderly -- Practical Choice of DOACs in Older Patients -- Conclusions -- References -- 9: The "Obesity Paradox"

and the Use of NOAC -- Introduction -- Obesity Paradox in NVAf Patients -- Obesity Paradox in VTE Patients -- Body Weight and Use of NOACS: Pharmacological Considerations -- NOACs Versus Warfarin Across BMI Groups: Current Clinical Evidences -- NVAf Patients -- Dabigatran -- Rivaroxaban -- Apixaban -- Edoxaban -- NOACs Overview in NVAf Obese Patients -- VTE Obese Patients -- Dabigatran, Apixaban, and Edoxaban -- Rivaroxaban -- NOACs Overview in VTE Patients -- NVAf and VTE Obese Patients: Overview of NOACS Use -- Discussion -- Conclusion -- References -- 10: Direct Oral

Anticoagulation in Cancer Patients -- Introduction -- Use of DOACs in AF Cancer Patients -- VTE in Cancer Patients: Are the DOACs Always the Best Choice? -- Primary Prevention of VTE in Cancer Patients -- Treatment of VTE in Cancer Patients -- Discussion -- Conclusion --

References -- 11: DOACs and Dementia in Patients with Atrial Fibrillation -- Introduction -- Atrial Fibrillation and Dementia -- Potential Mechanisms in the Association Between AF and Dementia --

Oral Anticoagulation and Dementia Risk -- DOACs and Dementia -- Future Directions -- Conclusions -- References -- 12: Non-vitamin K Antagonists and Cardiac Implantable Electronic Devices -- Introduction -- Pocket Hematomas -- Vitamin K Antagonists -- Non-vitamin K Oral Antagonists -- NOAC Interruption for CIED Surgery -- Concomitant Antiplatelet Therapy -- Predictors of Pocket Hematoma -- Anticoagulation of Patients with Subclinical Atrial Fibrillation -- Burden of SCAF -- Progression of SCAF -- Predictors of SCAF -- Anticoagulation for SCAF -- Ongoing Trials. References -- 13: Direct Oral Anticoagulants and Atrial Fibrillation Ablation -- Introduction -- Risk of Thromboembolism with AF Ablation -- Pre-ablation Anticoagulation Strategies -- Warfarin Management Periprocedurally -- DOAC Management Periprocedurally -- Intraprocedural Anticoagulation -- Postprocedural Anticoagulation -- Conclusions -- References -- 14: DOAC Therapy in Patients Post Left Atrial Appendage Occlusion or Isolation -- Stroke Reduction in Patients with Atrial Fibrillation -- Left Atrial Appendage Occlusion -- Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion -- Left Atrial Appendage Isolation -- Future Directions with Left Atrial Appendage Closure and Anticoagulation -- References -- 15: Use of Direct Oral Anticoagulants After Transcatheter Aortic Valve Replacement -- Introduction -- Technical Aspects of Transcatheter Bioprosthetic Heart Valves -- Thrombotic vs. Bleeding Risk -- Recent Percutaneous Coronary Intervention -- Atrial Fibrillation -- Cerebrovascular Complications -- Subclinical Leaflet Thrombosis -- Current Evidence and Future Perspectives -- References -- 16: Use of Direct Oral Anticoagulants After Percutaneous Coronary Intervention -- Introduction -- In the Middle of Ischemic and Bleeding Risk -- Lessons from Randomized Clinical Trials -- VKA in Triple Versus Dual Antithrombotic Therapy -- DOAC in Triple Versus Dual Antithrombotic Therapy -- PIONEER AF-PCI Trial -- RE-DUAL PCI Trial -- AUGUSTUS Trial -- ENTRUST-AF PCI Trial -- Meta-analysis -- Current Recommendations -- Practical Management of AF Patients Undergoing PCI -- Procedural and Peri-PCI Management -- Choice and Duration of Antithrombotic Therapy After PCI -- VKA in Triple Therapy in the DOAC Era: Is There Still Room? -- Other Interventional Strategies -- Conclusions -- References. 17: Direct Oral Anticoagulants and Left Ventricular Thrombosis: The Evidence for a Good Therapeutic Approach -- Introduction -- Epidemiology -- LVT in Dilated Cardiomyopathy -- High-Risk Patients -- Diagnostic Modalities -- Treatment Options -- Prevention of Embolic Events -- Treatment of Definite LVT -- Current International Guidelines -- Direct Oral Anticoagulants -- References -- Index.

---